TrialSignal
Clinical trial intelligence report
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03401060
Status
COMPLETED
Phase
PHASE3
Sponsor
Assistance Publique - Hôpitaux de Paris
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates the efficacy of Denosumab, an anti-RANKL monoclonal antibody, in improving bone mineral density (BMD) in patients with osteoporosis due to systemic mastocytosis. The study is sponsored by Assistance Publique - Hôpitaux de Paris and involves a randomized, double-blind design comparing Denosumab to a placebo over three years.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03401060
Indication
Osteoporosis
Modality
monoclonal antibody
Target
Osteoporosis associated with systemic mastocytosis
Intervention
Denosumab, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.